Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Enzalutamide + Taselisib
Indication/Tumor Type triple-receptor negative breast cancer
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown triple-receptor negative breast cancer not applicable Enzalutamide + Taselisib Phase Ib/II Actionable In a Phase Ib/II trial, the combination of Taselisib (GDC-0032) and Xtandi (enzalutamide) resulted in a clinical benefit rate of 35.7% (5/14) in patients with triple-negative breast cancer, with partial response in one patient and stable disease in 4 patients, compared to no clinical benefit with Xtandi (enzalutamide) alone, and PIK3CA mutations and AR expression did not correlate with response (PMID: 31822498; NCT02457910). 31822498
PubMed Id Reference Title Details
(31822498) TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Full reference...